drugset
drugset / Trial / NCT04103697

Neoadjuvant Chemotherapy in Patients With Intermediate Risk Upper and Mid Rectal Cancer

NCT04103697 ↗

Phase 3 Unknown 560 enrolled Blokhin's Russian Cancer Research Center
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether 4 cycles of neoadjuvant CapOx chemotherapy is more effective than the upfront surgery in patients with intermediate risk CRM"-" mid and upper rectal cancer.

Timeline

Start
2019-08-01
Primary completion
2024-08
Completion
2024-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule 825 mg/m2 Oral
Subject Capecitabine Small molecule 2000 mg/m2 Oral
Subject Oxaliplatin Small molecule 130 mg/m2 —

Indications

rectal carcinoma